对美国内科医师学会骨质疏松治疗指南的评述
该评述由国际骨质疏松基金会和欧洲骨质疏松、骨关节炎及肌肉骨骼疾病临床与经济学会认可,总结美国内科医师学会(ACP)近期关于治疗低骨密度或骨质疏松以预防骨折的指南的多项不足。ACP指南因基于T值而非骨折风险评估来推荐治疗,且未能充分考虑合成代谢疗法,在范围上存在欠缺。ACP指南似乎已过时。
要点
- ACP指南基于T值而非骨折风险评估推荐治疗,范围存在欠缺。
- ACP指南未能充分考虑合成代谢疗法。
- 评述认为ACP指南似乎已过时。
核心结论
- ACP指南似乎已过时。
研究设计与样本
- 文献综述及对ACP指南的批判性评述。
主要发现
- 指南因基于T值而非骨折风险评估来推荐治疗,在范围上存在欠缺。
- 指南未能充分考虑合成代谢疗法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This review, endorsed by the International Osteoporosis Foundation and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, summarizes several failings of the recent guidelines of the American College of Physicians (ACP) on the treatment of low bone density or osteoporosis to prevent fractures. INTRODUCTION: The ACP recently issued guidelines for the treatment of low bone density or osteoporosis to prevent fractures. METHODS: Literature review and critical review of the ACP guidelines. RESULTS: The guideline is lacking in scope due to the endorsement of treatment based on T-scores rather than fracture risk assessment and in failure to adequately consider anabolic therapies. CONCLUSIONS: The ACP guideline appears outdated.
引用
- Kanis JA, Cooper C, Rizzoli R, et al. Review of the guideline of the American College of Physicians on the treatment of osteoporosis. Osteoporos Int. 2018. PMID: 29869039. doi:10.1007/s00198-018-4504-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。